Omega Fund Management LLC Purchases 350,000 Shares of enGene Holdings Inc. $ENGN

Omega Fund Management LLC raised its position in enGene Holdings Inc. (NASDAQ:ENGN) by 66.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 876,357 shares of the company’s stock after purchasing an additional 350,000 shares during the quarter. enGene comprises approximately 2.8% of Omega Fund Management LLC’s investment portfolio, making the stock its 7th biggest holding. Omega Fund Management LLC owned 1.31% of enGene worth $7,914,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. PFS Partners LLC increased its stake in shares of enGene by 22.2% in the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after purchasing an additional 2,000 shares during the period. Millennium Management LLC increased its stake in shares of enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares during the period. Raymond James Financial Inc. increased its stake in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Cresset Asset Management LLC acquired a new stake in shares of enGene in the second quarter valued at approximately $36,000. Finally, Paloma Partners Management Co acquired a new stake in shares of enGene in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen lowered shares of enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Morgan Stanley lowered shares of enGene from an “overweight” rating to an “equal weight” rating in a research note on Friday, May 8th. Citizens Jmp lowered shares of enGene from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. HC Wainwright lowered their price objective on shares of enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, UBS Group lowered their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, enGene currently has a consensus rating of “Hold” and a consensus price target of $12.50.

enGene Price Performance

NASDAQ ENGN opened at $1.75 on Wednesday. enGene Holdings Inc. has a 12 month low of $1.40 and a 12 month high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. The firm has a market capitalization of $117.23 million, a PE ratio of -0.81 and a beta of -0.30. The company’s 50 day simple moving average is $4.21 and its 200 day simple moving average is $7.15.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Monday, June 15th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same quarter last year, the business posted $0.51 EPS. As a group, equities research analysts forecast that enGene Holdings Inc. will post -2.02 EPS for the current fiscal year.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.